Caricamento quotazioni...
Previsioni
Non sono disponibili dati degli analisti per questa azienda.
Discussioni nella community
Non ci sono ancora discussioni su questo asset.
Avvia discussioneNotizie Vai al feed delle notizie
Uniphar increases profit in H1 2026 and confirms EBITDA target for 2028
Uniphar reports adjusted EPS of EUR 0.109 in H1 2026 (+11.2%), gross profit of EUR 236.5m (+7.7%) and EBITDA of EUR 61.1m (+6.2%). Return on capital employed (ROCE) was 14.7%, and free cash flow was negative at EUR -47m, which is attributed to timing effects in working capital. Management reaffirmed the mid‑term target of EUR 200m EBITDA by 2028 and expects double‑digit growth in Pharma and continued growth in Medtech; the commissioning of the new Greenogue 2 distribution centre has been delayed to February 2027. » Altro su de.investing.com
Uniphar executives trade shares from remuneration plan
Senior executives of Uniphar carried out share purchases and sales under the company’s share-based remuneration plan through the Uniphar plc Employee Benefit Trust. CEO Gerard Rabbette bought 111,088 ordinary shares and sold 233,068 ordinary shares; CFO Timothy Dolphin bought 74,059 and sold 155,378 ordinary shares — all transactions at €3.8629 per share. After the transactions Rabbette holds 7,334,772 and Dolphin holds 5,610,856 ordinary shares. The dealings were reported on Euronext Dublin via Intertrust Trustee (Ireland) Limited as trustee and are based on a disclosure under Article 19 of the Market Abuse Regulation. » Altro su de.investing.com
Uniphar schedules general meeting for 7 May and sends annual report
Uniphar has scheduled its annual general meeting for 7 May 2026 at 11:00 in the premises of William Fry LLP in Dublin and has sent the annual report for the year ended 31 December 2025 to shareholders. Shareholders may attend in person, vote by proxy, or follow the meeting by telephone as listeners only; questions must be submitted in writing with the shareholder reference number by 5 May 2026 at 17:00. The notice, proxy form and annual report are available on the company website and for inspection at the registered office during normal business hours. » Altro su de.investing.com
Uniphar reports 9% organic gross profit growth and beats 2025 earnings expectations
Uniphar recorded 9% organic gross profit growth in 2025 and adjusted earnings per share that rose by around 21%, outperforming the 14% consensus forecast. Drivers included lower financing costs and effects from a €35m share buyback programme. Net debt at year-end stood at 1.5x EBITDA, roughly €90m below analyst expectations, supported by positive working capital. Uniphar confirms its target to reach €200m EBITDA by 2028 (including €20m from M&A) and sets 2026 growth targets for its divisions: Pharma (double-digit), Medtech (high single-digit) and Supply Chain & Retail (low single-digit); the new logistics centre and ERP remain on schedule for the summer. » Altro su de.investing.com
Santhera agrees exclusive distribution deal for AGAMREE with Uniphar for five GCC states
Santhera Pharmaceuticals has signed an exclusive distribution partnership with Uniphar for AGAMREE (Vamorolone) in the United Arab Emirates, Saudi Arabia, Kuwait, Oman and Bahrain; sales via a named-patient program are due to start in Q1 2026, with broader commercial distribution expected after approval at the end of 2026. Santhera will receive sales-based compensation and stresses that the agreement is intended to accelerate access to the therapy for DMD patients in the region. The drug is already approved in several regions and Santhera names additional licensing partners for certain markets. » Altro su finanzen.net
Dividendi storici Dividendi
Tutte le metriche sui dividendi Tutte le metricheDati finanziari dell'azienda
| (EUR) | giugno 2026 | YoY |
|---|---|---|
| Ricavi | 1,57 Mld | - |
| Utile lordo | 216,56 Mln | - |
| Utile netto | 19,73 Mln | - |
| EBITDA | 57,87 Mln | - |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 1,13 Mld € |
Numero di azioni | 259,57 Mln |
Massimo/minimo a 52 settimane | 5,14 € - 3,53 € |
Rendimento da dividendo | 0,47% |
Dividendi TTM | 0,0205 € |
Beta | 1,16 |
Rapporto P/E | 21,01 |
Rapporto PEG | -1,31 |
Rapporto P/B | 2,62 |
Rapporto P/S | 0,36 |
Profilo aziendale
Uniphar plc opera come società diversificata di servizi sanitari nella Repubblica d'Irlanda, nel Regno Unito e a livello internazionale. La società opera attraverso tre divisioni: Commercial & Clinical, Product Access e Supply Chain & Retail. La divisione Commercial & Clinical offre servizi esternalizzati di vendita, marketing e gestione multicanale degli account ai produttori farmaco-medicali, nonché servizi di distribuzione e supporto ai produttori di dispositivi medici. La divisione Product Access fornisce servizi on demand, che garantiscono l'accesso a prodotti e trattamenti farmaco-medicali sviluppando relazioni e interazioni di valore tra i produttori e gli altri stakeholder del settore sanitario; e servizi di accesso esclusivo, che offrono partnership di distribuzione su misura ai partner farmaceutici per marchi chiave. La divisione Supply Chain & Retail si occupa di distribuzione pre-grossistica e grossistica di prodotti farmaceutici, sanitari e per la salute animale verso farmacie, ospedali e veterinari; e gestisce una rete di farmacie con i marchi Life, Allcare e Hickey's. Offre inoltre supporto farmaceutico, gestione della catena di approvvigionamento farmaceutica, assistenza infermieristica specialistica e infusionale, distribuzione di dispositivi medici, tecnologie sanitarie, data intelligence e servizi di consulenza, consulenza farmaceutica, medical affairs e servizi di farmacia online e product fostering, oltre a soluzioni di dati per l'industria farmaceutica. Uniphar plc è stata fondata nel 1967 ed ha sede a Dublino, in Irlanda.
| Nome | UNIPHAR PLC EO -,08 |
| CEO | Gerard Rabbette |
| Sede centrale | Dublin,
du Irlanda |
| Sito web | |
| Quotazione in borsa | 17/07/2019 |
| Dipendenti | 3500 |
Deep Dive
Simboli di borsa
| Borsa | Simbolo |
|---|---|
London Stock Exchange | UPR.L |
Frankfurt | 0NR.F |
London | UPR.L |
München | 0NR.MU |
Düsseldorf | 0NR.DU |